Cancer Research · global
Seeking Treatment Clues in Protein Structure: firmonertinib Shows Activity in Rare EGFR Lung Cancer Mutations
An early trial involving 60 patients adds clinical evidence for lung cancer with EGFR PACC mutations. Tumor responses were seen at both doses, but whether the drug can outperform existing targeted therapies remains a question for a randomized phase 3 trial.
Lung cancers with EGFR mutations do not necessarily respond in the same way to targeted drugs. For patients with rare mutations, the challenge is often a lack of sufficient evidence to guide drug selection. The phase 1b FURTHER trial, announced by MD Anderson Cancer Center on October 16 and published in *Cancer Cell*, offers new clues for a group of mutations known as PACC: the investigational drug firmonertinib showed antitumor activity in some patients.
The study began by examining how mutations alter protein shape. PACC refers to a class of mutations that compress the P-loop and αC-helix regions of the EGFR protein. The research team sought to understand drug responses based on structural changes, rather than classifying mutations solely by their location in the gene. According to the center, features of firmonertinib’s chemical structure help it bind to these mutant proteins.
Registry information from the U.S. National Cancer Institute confirms that FURTHER, identified as FURMO-002 and NCT05364073, is an open-label, multicenter study led by ArriVent BioPharma, with dose-escalation and expansion stages. Its cohort 4 for uncommon EGFR mutations excludes exon 20 insertion mutations and patients who have previously received an EGFR tyrosine kinase inhibitor. However, it allows some patients who have received other treatments, so “EGFR targeted therapy-naive” and “treatment-naive” cannot be treated as interchangeable.
The published PACC analysis included 60 patients with advanced non-small cell lung cancer. Among previously untreated patients, objective response rates were 43% in the 160 mg daily group and 68% in the 240 mg daily group, meaning tumor shrinkage met predefined assessment criteria. These two percentages apply to untreated patients and cannot be taken directly as the overall response rates for all 60 patients, nor do they represent cure rates.
The study also observed responses in brain lesions. According to the center, among 17 patients with brain metastases at the start of treatment, 47% had intracranial tumor shrinkage and 41% achieved a complete response. This provides a reason for further research into treating brain metastases, but the number of patients was limited, and a complete response on imaging cannot be equated with eradication of the cancer.
The findings must still be interpreted within the limits of an early trial. This was not a randomized controlled trial designed to demonstrate that firmonertinib is superior to existing drugs, and the difference in response rates between the two dose groups is insufficient on its own to establish which dose is better. The center’s press release did not provide the full distribution and severity of adverse events, so efficacy figures alone cannot establish the overall benefits and risks. The study was funded by ArriVent.
The next key step is the randomized phase 3 ALPACCA trial, which is already underway. According to the design presented at ASCO in 2026, the study plans to enroll approximately 480 patients and compare firmonertinib at 240 mg daily with the physician’s choice of osimertinib or afatinib, primarily assessing progression-free survival and objective response rate. This direct comparison will be better positioned to answer whether a treatment selected based on mutation structure can provide better disease control for patients with PACC mutations than existing options.